189 results about "Antibiotic Agents" patented technology

The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

The invention relates to synthetic, bioabsorbable polymer materials and implants, like fibres, sutures, meshes and other tissue management, wound closure or tissue engineering devices, which contain: a) a bioabsorbable polymeric matrix; b) antibiotic and/or anti-inflammatory agent particles or mixture thereof, dispersed in the matrix, and c) optionally an additive agent to facilitate device recognition and/or handling to facilitate the use and application of finalized product. In the matrix, cavities around the particles are induced by mechanical processing of the matrix phase. A preferred embodiment of the present invention is a device (suture) that provides a sustained release of antibiotic agent over several days to several weeks for the prevention or treatment of infection. The sutures may be effectively implanted into or in the vicinity of: 1) infected tissue, 2) potentially infected tissue, or in tissues where infection, should it occur, leads to disastrous consequences.

Methods of identifying subjects at increased risk of cancer, based upon detection of biofilms and/or biofilm-associated microbes within a subject, are disclosed. Therapies designed to prevent formation and/or reduce the size of biofilms in a subject identified to be at increased risk of cancer based upon detection of biofilms and/or biofilm-associated microbes are disclosed. In particular embodiments, the invention provides for identification of a subject at elevated risk of developing or having colorectal cancer and/or a colorectal adenoma, based upon detection of a biofilm and/or biofilm-associated bacteria within the gastrointestinal tract of the subject (optionally, within a biopsy specimen and/or stool sample of such subject). Therapies involving administration of an antibiotic agent and/or a probiotic agent to a subject, to prevent or reduce biofilm formation within the gastrointestinal tract of the subject, optionally provided in combination with additional cancer therapy, are also disclosed.

The present invention provides a therapeutic method for treating biological diseases that includes the administration of an effective amount of a suitable antibiotic agent, antifungal agent or antiviral agent in conjunction with an A_2A adenosine receptor agonist. If no anti-pathogenic agent is known the A_2A agonist can be used alone to reduce inflammation, as may occur during infection with antibiotic resistant bacteria, or certain viruses such as those that cause SARS or Ebola. Optionally, the method includes administration of a type IV PDE inhibitor.

The present invention relates to compositions comprising a combination of one or more antiseptic and an antibiotic. It is based, at least in part, on the discovery that such combinations tend to deter the formation of antibiotic-resistant organisms. In preferred, nonlimiting embodiments of the invention, the antibiotic is minocycline and the antiseptic is a chlorhexidine compound, triclosan, or benzalkonium chloride, and in particular embodiments, a silver salt or a bismuth salt is added. Examples of specific, nonlimiting embodiments of the invention include combinations of (i) minocycline, triclosan, and a bismuth salt; (ii) minocycline, a chlorhexidine compound, and a bismuth salt; and (iii) minocycline, benzalkonium chloride, and a bismuth salt. The present invention further provides for articles, such as, but not limited to, medical articles, which have been treated with or which otherwise comprise a combination of antiseptic and antibiotic.

The invention discloses antibiotic fiber and a preparation method of fiber product. According to the invention, an aqueous nano-grade silver antibiotic agent is prepared into organic nano-grade silver sol by using a chemical phase transferring method, such that the antibiotic agent has a good compatibility with a high polymer substrate; the sol is directly mixed with high polymer, and the mixture is dried, such that an antibiotic high polymer is prepared. The obtained antibiotic high polymer has characteristics of good versatility, good dispensability, simple technology, good processability, good temperature tolerance, and no environmental pollution. With methods of spinning or melt blowing, the antibiotic high polymer can be directly used for preparing antibiotic fibers and antibiotic fiber products. The obtained antibiotic fibers and antibiotic fiber products have excellent performances of rapid and long-lasting antibiotic effect. The physical properties of the antibiotic fibers and the antibiotic fiber products are not changed with additional antibiotic agents.

A face mask structure, which includes an outer protective layer prepared from a water-repellent non-woven fabric; an inner protective layer prepared from a hydrophile non-woven fabric; a filter layer prepared from a static high-density fiber material for filtering microbes and dust powder, and sandwiched between the outer and inner protective layers; and a compound layer treated with a multiple functionalize carboxylic acid derivative that is a product from a chemical reaction between a cyclodextrin complex and a multiple functionalize carboxylic acid. The cyclodextrin complex can be a complex of cyclodextrin and an essential oil, antibiotic agent, or mosquito repellent agent.

The invention relates to a composite antibiotic finishing agent for textiles. The composite antibiotic finishing agent for textiles comprises the following raw materials, by weight, 1-5% of polyhexamethylene guanidine, 5-10% of betaine, 1-5% of nano-zinc oxide, 1-5% of chitosan, 0.5-2% of a surfactant, 5-10% of an organic solvent and 0.1-0.5% of essence. With the application of various antibiotic agents for a synergetic antibiotic effect, the composite antibiotic finishing agent for textiles has high heat resistance and strong antibiotic property, is safe and reliable, is green and environmentally friendly, and can be used in antibiotic finish of various textiles.

The invention provides a splinting orthopedic or a rehabilitative product that has an increased resistance to odor and/or microbial growth. More particularly, the invention provides for a moldable splinting orthopedic or a rehabilitative product comprising an antibiotic agent and low temperature thermoplastic polymer.

The invention relates to the technical field of textile application, in particular to an antibiotic fiber, a preparation method thereof and an application thereof in home textile, aiming at solving the problem that the prior fiber product is poor in antibiotic effect and can not ensure antibiotic effect. The invention provides an antibiotic fiber which comprises antibiotic agent and fiber, the antibiotic agent at least comprises nano particles which comprises nano titanium dioxide antibiotic agent and Ag ion, the antibiotic agent is added on the fiber by a cross-linking agent to form antibiotic fiber, the antibiotic fiber of the invention has the characteristics of good effect and long lasting time of antibiotic capability.

A method for treating diseases associated with abnormal cell proliferation comprises delivering to a patient in need of treatment a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, prodrug of 20(S)-camptothecin, and pharmaceutically active metabolite of 20(S)-camptothecin, in combination with an effective amount of one or more agents selected from the group consisting of alkylating agent, antibiotic agent, an alkylating agent, antibiotic agent, antimetabolic agent, hormonal agent, plant-derived agent, anti-angiogenesis agent and biologic agent. The method can be used to treat benign tumors, malignant or metastatic tumors, leukemia and diseases associated with abnormal angiogenesis.

The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.

Methods and compositions for treating and preventing sepsis are provided. The methods of the invention comprise administering to a subject a therapeutically effective amount of an A1 adenosine receptor antagonist in combination with an antibiotic agent. The invention further encompasses pharmaceutical compositions comprising a combination of an A1 adenosine receptor antagonist and an antibiotic agent in a pharmaceutically acceptable carrier. The pharmaceutical compositions of the invention find use in methods for treating and preventing sepsis.

The invention relates to products comprising an antibiotic agent and a second agent being a dispersant or an anti-adhesive agent, in particular a mucolytic dispersant or a mucolytic anti-adhesive agent, which are useful in relation to the prevention and treatment of bacterial infections.

A nano-class RE antibacterial agent with core-shell structure for plastics, paine and ceramics is prepared from binary RE-heterocyclic compound match composed of RE ions chosen from La, Ce, Pr, Nd, Sm, Er, Eu, Y, Dy and Gd and the heterocyclic compound (imidazole or benzimidazole), and the carrier chosen from spherical SiO2 or spherical meta-porous SiO2. Its preparing process is also disclosed.

The present invention discloses an inorganic anti-bacterial and anti-midew additive which can be used in the various products of plastic, ceramics, enamels, paints, paper, textile and detergent. It is characterized by that it adopts the bisque powder as main raw material through the following steps: drying said bisque powder, adding water and stirring, adding ammonium nitrate, zinc nitrate and silver nitrate aqueous solution, stirring them, cleaning, filtering, drying and pulverizing so as to obtain the product. It is stable in performance, can resist high-temp. and its production process is simple, low in cost and its application is extensive.

Simple carboxylic acids, in particular dicarboxylic acids such as citric acid shows an unexpected ability to enhance the antimicrobial power of a wide range of disinfectant and/or antibiotic agents. As little as 1% citrate greatly enhances the ability of antibiotics to kill or inhibit a wide range of bacterial species including antibiotic resistant strains. Citrate alone is effective in preventing bacterial growth in platelet concentrates and in red blood cell suspensions. Effective concentrations of citrate cause little if any damage to blood cells. Besides enhancing the power of antibiotics citrate also enhances the antimicrobial properties of disinfectant organic dyes such as crystal violet and methylene blue. In addition citrate enhances the antimicrobial properties of polyphenols of plant origin. Iodine-based disinfectants are also enhanced without enhancing protein denaturation.

Disclosed are cosmetic preparations and, more particularly, skin and hair care and cleaning products with an amount of at least one glycyrrhetic antibacterial agent selected from glycyrrhetic acid, glycyrrhetic acid derivatives and extracts of Glycyrrhiza glabra, and their salts, effective to inhibit or prevent the growth of bacteria. The cosmetic preparations may include other antibacterial or antibiotic agents. The glycyrrhetic antibacterial agent and, optionally, the antibacterial or antibiotic agents may be provided in microencapsulated form. Also disclosed is the use of such cosmetic preparations for treating acne.

A Silicibacter sp. strain useful for genetic transformation of marine algae and production of antibiotic agents is described. Silicibacter sp. TM1040 is a genetically tractable member of the marine Roseobacter clade of bacteria that forms an intimate and obligate interaction with algae, and is useful as a probiotic for producing antibacterial agents that are cidally effective against pathogenic bacteria such as Mycobacterium marinum, Vibrio anguillarum, V. coralliilyticus, and V. shiloi bacteria.

The invention relates to soldering fluid technique, which is a modified technique based on prior art, specifically relates to a mildew resistant antibiotic low-corrosivity water-based soldering fluid, comprising components with following percentage by weight (): 1.0% of active agent, 1.0% of micro-enwrapping agent, 0.1% of surfactant, 0.01% of mildew resistant antibiotic agent, residue is solvent of de-ionized water, and the weight sum of each components are 100 The advantages of the invention are: the soldering fluid contains no volatile organic matter or halide, and can inhibit development of microorganisms such as bacteria and fungi and mildew; circuit and conveyor are not eroded during welding, no cleaning is needed after welded, and the soldering fluid is safe and environmentally-friendly; the soldering fluid can be coated on the PCB plate weld face by spraying, dipping or foaming mode to implement leadless welding of electronic products. The invented soldering fluid is practical and has great market potential.

This invention relates to a novel class of antibiotic agents, more specifically to macrolides comprising an oxazolidinone structure, their preparation, pharmaceutical compositions containing them, their use and methods of treatment using them.